WHO Drug Information, Vol. 14, No. 3, 2000
RECOMMENDED INN: List 44
International Nonproprietary Names for Pharmaceutical Substances (INN) RECOMMENDED International Nonproprietary Names (Rec. INN): List 44 Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution EB15.R7); 1969, 173, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–73) and Recommended (1–35) International Nonproprietary Names can be found in Cumulative List No. 9, 1996.
Dénominations communes internationales des Substances pharmaceutiques (DCI) Dénominations communes internationales RECOMMANDÉES (DCI Rec): Liste 44 Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond. Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisises par l’Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie. On trouvera d’autres listes de Dénominations communes internationales proposées (1–73) et recommandées (1– 35) dans la Liste récapitulative No. 9, 1996.
Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI) Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 44 De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución EB15.R7); 1969, 173, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia. Las listas de Denominaciones Comunes Internacionales Propuestas (1–73) y Recomendadas (1–35) se encuentran reunidas en Cumulative List No. 9, 1996.
183
RECOMMENDED INN: List 44
WHO Drug Information, Vol. 14, No. 3, 2000
Proposed INN (Latin, English, French, Spanish) DCI Proposée DCI Propuesta
Chemical name or description: Action and use: Molecular formula Chemical Abstracts Service (CAS) registry number: Graphic formula Nom chimique ou description: Propriétés et indications: Formule brute Numéro dans le registre du CAS: Formule développée Nombre químico o descripción: Acción y uso: Fórmula empírica Número de registro del CAS: Fórmula desarrollada
adalimumabum adalimumab
immunoglobulin G 1 (human monoclonal D2E7 heavy chain anti-human tumor necrosis factor), disulfide with human monoclonal D2E7k-chain, dimer immunoglobuline G1, anti-(facteur a de nécrose tumorale humain) (chaîne lourde de l’anticorps monoclonal humain D2E7), dimère du disulfure avec la chaîne k de l’anticorps monoclonal humain D2E7 inmunoglobulina G1 (anti-factor a de necrosis tumoral humano), dímero del disulfuro de la cadena pesada D2E7 monoclonal humana con la cadena k D2E7 monoclonal humana
adalimumab
adalimumab
adrogolidum adrogolide
(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propylbenzo[f]thieno[2,3c]quinoline-9,10-diol diacetate (ester) diacétate de (5aR,11b S)-2-propyl-4,5,5a,6,7,11b-hexahydrobenzo[f]thieno= [2,3-c]quinoléine-9,10-diyle diacetato (éster)de (5aR,11bS)-4,5,5a,6,7,11b-hexahidro-2-propilbenzo= [f]tieno[2,3-c]quinolina-9,10-dilo C22H25NO4S H3C S H3C O H3C O O O H NH H
adrogolide
adrogolida
alemcinalum alemcinal
8,9-didehydro-N-demethyl-9-deoxo-4'’,6,12-trideoxy-6,9-epoxyN-ethylerythromycin (2R,3S,4R,5R,8R,9S,10S,11R,12R)-5-éthyl-11-[[3-(éthylméthylamino)3,4,6-tridésoxy-b-D -xylo-hexopyranosyl]oxy]-3-hydroxy2,4,8,10,12,14-hexaméthyl-9-[(3-C-méthyl-3-O-méthyl-2,4,6-tridésoxya-L-erythro-hexopyranosyl)oxy]-6,15-dioxabicyclo[10.2.1]pentadec-1(14)én-7-one
alemcinal
184
WHO Drug Information, Vol. 14, No. 3, 2000
RECOMMENDED INN: List 44
alemcinal
8,9-dideshidro-N-desmetil-9-desoxo-4'’,6,12-tridesoxi-6,9-epoxiN-etileritromicina C38H67NO10 CH3 H H CH3 H CH3 O H CH3
H3C CH3 O O H3C N CH3 OH O CH3 OCH3 CH3 H H3C O HO H CH3 O H
OH
altiniclinum altinicline altinicline altiniclina
(-)-5-ethynylnicotine (-)-3-éthynyl-5-[(2S)-1-méthylpyrrolidin-2-yl]pyridine (-)-5-etinilnicotina C12H14N2 N
CH3 N H
CH
amiglumidum amiglumide amiglumide
(R)-4-(2-naphthamido)-N,N-dipentylglutaramic acid acide (4R)-5-(dipentylamino)-4-[(naphtalén-2-ylcarbonyl)amino]5-oxopentanoïque (R)-4-(2-naftamido)-N,N-dipentilglutarámico C26H36N2O4 CO2H O H N H N O CH3 CH3
amiglumida
185
RECOMMENDED INN: List 44
WHO Drug Information, Vol. 14, No. 3, 2000
anisperimusum anisperimus
[(6-guanidinohexyl)carbamoyl]methyl [4-[[(R)-3-aminobutyl]amino]butyl]= carbamate [4-[[(3R)-3-aminobutyl]amino]butyl]carbamate de 2-[(6-guanidinohexyl)amino]-2-oxoéthyle [4-[[(R)-3-aminobutil]amino]butil]carbamato de [(6-guanidinohexil)carbamoil]metilo C18H39N7O3 NH H2N N H O O O N H
anispérimus
anisperimus
H N
H N
NH2 H CH3
ataquimastum ataquimast ataquimast ataquimast
1-ethyl-3-(methylamino)-2(1H)-quinoxalinone 1-éthyl-3-(méthylamino)quinoxalin-2(1H)-one 1-etil-3-(metilamino)-2(1H)-quinoxalinona C11H13N3O O H3C N N
H N
CH3
axitiromum axitirome
ethyl (±)-4'-[[a-(p-fluorophenyl)-a,4-dihydroxy-m-tolyl]oxy]3',5'-dimethyloxanilate [[4-[3-[( RS )-(4-fluorophényl)hydroxyméthyl]-4-hydroxyphénoxy]3,5-diméthylphényl]amino]oxoacétate d'éthyle (±)-4'-[[a-(p-fluorofenil)-a,4-dihidroxi-m-tolil]oxi]-3',5'-dimetiloxanilato de etilo C25H24FNO6 O O O CH3 CH3 and enantiomer et énantiomère y enantiómero
axitirome
axitiromo
F
HO
H3C O
H N
H OH
186
WHO Drug Information, Vol. 14, No. 3, 2000
RECOMMENDED INN: List 44
bilastinum bilastine
p-[2-[4-[1-(2-ethoxyethyl)-2-benzimidazolyl]piperidino]ethyl]a-methylhydratropic acid acide 2-[4-[2-[4-[1-(2-éthoxyéthyl)-1H-benzimidazol-2-yl]pipéridin1-yl]éthyl]phényl]-2-méthylpropanoïque ácido p-[2-[4-[1-(2-etoxietil)-2-bencimidazolil]piperidino]etil]a-metilhidratrópico C28H37N3O3 H3C CH3 H3C O N N N CO2H
bilastine
bilastina
binetrakinum binetrakin binétrakine binetrakina
interleukin 4 (human) interleukine 4 humaine interleuquina 4 (humana)
HKCDITLQEI EKETFCRAAT RFLKRLDRNL REKYSKCSS
IKTLNSLTEQ VLRQFYSHHE WGLAGLNSCP
KTLCTELTVT KDTRCLGATA VKEANQSTLE
DIFAASKNTT QQFHRHKQLI NFLERLKTIM
cangrelorum cangrelor
N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-5'-adenylic acid, monoanhydride with (dichloromethylene)diphosphonic acid monoanhydride dichlorométhylènediphosphonique N-[2-(méthylsulfanyl) éthyl]-2-[(3,3,3-trifluoropropyl)sulfanyl]-5’-adénylique monoanhidrido del ácido N-[2-(metiltio)etil]-2-[(3,3,3-trifluoropropil)tio]5'-adenílico con ácido (diclorometileno)difosfónico
cangrélor
cangrelor
187
RECOMMENDED INN: List 44
WHO Drug Information, Vol. 14, No. 3, 2000
C17H25Cl2F3N5O12P3S2 H3C S N F3C HO HO P Cl Cl P O P S O O N NH N N
O HO O O OH
OH OH
cetuximabum cetuximab
immunoglobulin G 1 (human-mouse monoclonal C225 g1-chain anti-human epidermal growth factor receptor), disulfide with human-mouse monoclonal C225 k-chain, dimer immunoglobuline G1, anti-(récepteur du facteur de croissance humain de l’épiderme) (chaîne g1 de l’anticorps monoclonal chimérique homme-souris C225), dimère du disulfure avec la chaîne k de l’anticorps monoclonal chimérique homme-souris C225 inmunoglobulina G 1, anti-(receptor del factor humano de crecimiento de la epidermis)(cadena g1-del anticuerpo monoclonal quimérico hombre-ratón C225), dímero del disulfuro con la cadena k del anticuerpo monoclonal quimérico hombre-ratón C225
cétuximab
cetuximab
cilomilastum cilomilast
cis -4-cyano-4-[3-(cyclopentyloxy)-4methoxyphenyl]cyclohexanecarboxylic acid acide cis-4-cyano-4-[3-(cyclopentyloxy)4-méthoxyphényl]cyclohexanecarboxylique ácido cis-4-ciano-4-[3-(ciclopentiloxi)-4-metoxifenil]ciclohexanocarboxílico C20H25NO4 H3CO O
cilomilast
cilomilast
CO2H H NC
conivaptanum conivaptan
4'’-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]2-biphenylcarboxanilide N-[4-[(2-méthyl-4,5-dihydroimidazo[4,5-d][1]benzaépin-6(1H)yl)carbonyl]phényl]biphényle-2-carboxamide 4'’-[(4,5-dihidro-2-metilimidazo[4,5-d][1]benzazepin-6(1 H)-il)carbonil]2-bifenilcarboxanilida
conivaptan
conivaptán
188
WHO Drug Information, Vol. 14, No. 3, 2000
RECOMMENDED INN: List 44
C32H26N4O2
O O N H N NH N CH3
crobenetinum crobenetine
(2 R,6S)-3-[(2S)-2-(benzyloxy)propyl]-1,2,3,4,5,6-hexahydro-6,11,11trimethyl-2,6-methano-3-benzazocin-10-ol (2R,6S)-3-[(2S)-2-(benzyloxy)propyl]-6,11,11-triméthyl-1,2,3,4,5,6hexahydro-2,6-méthano-3-benzazocin-10-ol (2R,6S)-3-[(2S)-2-(benciloxi)propil]-1,2,3,4,5,6-hexahidro-6,11,11-trimetil2,6-metano-3-benzazocin-10-ol C25H33NO2 OH H N CH3 CH3 O H CH3
crobénétine
crobenetina
CH3
cystinum cystine cystine cistina
L-cystine L-cystine L-cistina
C6H12N2O4S2 H NH2 HO2C H NH2 S S CO2H
darusentanum darusentan darusentan darusentán
(+)-( S)-2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-3-methoxy-3,3diphenylpropionic acid (+)-acide (2S)-2-(4,6-diméthoxypyrimidin-2-yloxy)-3-méthoxy3,3-diphénylpropanoïque ácido (+)-(S)-2-[(4,6-dimetoxi-2-pirimidinil)oxi]-3-metoxi-3,3-difenilpropiónico
189
RECOMMENDED INN: List 44
WHO Drug Information, Vol. 14, No. 3, 2000
C22H22N2O6 CO2H H N H3CO O N OCH3
OCH3
donitriptanum donitriptan donitriptan donitriptán
1-[[[3-(2-aminoethyl)indol-5-yl]oxy]acetyl]-4-(p-cyanophenyl)piperazine 1-[2-[[3-(2-aminoéthyl)-1 H-indol-5-yl]oxy]acétyl]-4-(4cyanophényl)pipérazine 1-[[[3-(2-aminoetil)indol-5-il]oxi]acetil]-4-(p-cianofenil)piperazina C23H25N5O2 NC H N N O O NH2
N
doxercalciferolum doxercalciferol doxercalciférol doxercalciferol
(5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraene-1a,3 b-diol (5Z,7E,22E)-9,10-sécoergosta-5,7,10(19),22-tétraène-1a,3 b-diol (5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraeno-1a,3 b-diol C28H44O2 H3C H CH3 H H3C H H
CH3 CH3
CH2 HO H H OH
emfilerminum emfilermin emfilermine emfilermina
leukemia-inhibiting factor (human) facteur d’inhibition leucémique humain factor inhibidor de leucemia (humano)
190
WHO Drug Information, Vol. 14, No. 3, 2000
RECOMMENDED INN: List 44
SPLPITPVNA FILYYTAQGE VELYRIVVYL ILRGLLSNVL LGCQLLGKYK
TCAIRHPCHN PFPNNLDKLC GTSLGNITRD CRLCSKYHVG QIIAVLAQAF
NLMNQIRSQL GPNVTDFPPF QKILNPSALS HVDVTYGPDT
AQLNGSANAL HANGTEKAKL LHSKLNATAD SGKDVFQKKK
emivirinum emivirine émivirine emivirina
6-benzyl-1-(ethoxymethyl)-5-isopropyluracil 6-benzyl-1-(éthoxyméthyl)-5-(1-méthyléthyl)pyrimidine-2,4(1H,3H)-dione 6-bencil-1-(etoximetil)-5-isopropiluracilo C17H22N2O3 O HN O H3 C O N CH3 CH 3
entecavirum entecavir
9-[(1S,3 R,4 S)-4-hydroxy-3-(hydroxymethyl)-2methylenecyclopentyl]guanine 2-amino-9-[(1 S,3R,4S )-4-hydroxy-3-(hydroxyméthyl)2-méthylènecyclopentyl]-1,9-dihydro-6H-purin-6-one 9-[(1S,3R,4S)-4-hidroxi-3-(hidroximetil)-2-metilenociclopentil]guanina C12H15N5O3 O HN H2N N H N N CH2 H OH H OH
entécavir
entecavir
epitumomabum epitumomab épitumomab
mouse IgG 1 monoclonal antibody which binds the human muc-1 gene product immunoglobuline G2a, anti-(antigène CD20 humain) (chaîne g2a de lanticorps monoclonal de souris B1R1), dimère du disulfure avec la chaîne l de lanticorps monoclonal de souris B1R1 191
RECOMMENDED INN: List 44
WHO Drug Information, Vol. 14, No. 3, 2000
epitumomab
inmunoglobulina G2a, anti-(antígeno CD20 humano) (cadena g2a del anticuerpo monoclonal de ratón B1R1), dímero del disulfuro con la cadena l del anticuerpo monoclonal de ratón B1R1
epratuzumabum epratuzumab
immunoglobulin G (human-mouse monoclonal IMMU-hLL2 g-chain anti-human antigen CD22), disulfide with human-mouse monoclonal IMMU-hLL2 k-chain, dimer immunoglobuline G, anti-(antigène CD22 humain) (chaîne g de lanticorps monoclonal de souris IMMU-hLL2 humanisé), dimère du disulfure avec la chaîne k de lanticorps monoclonal de souris IMMU-hLL2 humanisé inmunoglobulina G, anti-(antígeno CD22 humano)(cadena g del anticuerpo monoclonal humanizado de ratón IMMU-hLL2) dímero del disulfuro con la cadena k del anticuerpo monoclonal humanizado de ratón IMMU-hLL2
épratuzumab
epratuzumab
eptapironum eptapirone eptapirone eptapirona
4-methyl-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- as-triazine-3,5(2H,4 H)dione 4-méthyl-2-[4-[4-(pyrimidin-2-yl)pipérazin-1-yl]butyl]-1,2,4-triazine-3,5(2H,4H)dione 4-metil-2-[4-[4-(2-pirimidinil)-1-piperazinil]butil]-as-triazina-3,5(2H,4H)-diona C16H23N7O2 O N O
N N N N N N
H3C
escitalopramum escitalopram escitalopram escitalopram
(+)-(S)-1-[3-(dimethylamino)propyl]-1-(p-fluorophenyl)-5-phthalancarbonitrile (+)-(1S)-1-[3-(diméthylamino)propyl]-1-(4-fluorophényl)1,3-dihydroisobenzofurane-5-carbonitrile (+)-(S)-1-[3-(dimetilamino)propil]-1-(p-fluorofenil)-5-ftalancarbonitrilo C20H21FN2O F
N O NC
CH3
CH3
192
WHO Drug Information, Vol. 14, No. 3, 2000
RECOMMENDED INN: List 44
evernimicinum evernimicin
O-(1R)-2,3-O-methylene-4-O-(6-methyl-b-resorcyloyl)- D -xylopyranosylidene-(1 3-4)- a-L-lyxopyranosyl O-2,3,6-trideoxy-3-C-methyl-4-O-methyl-3-nitro-a-Larabino-hexopyranosyl-(1 ®3)-O-2,6-dideoxy-4- O-(3,5-dichloro-6-methoxy-4,2cresotoyl)-b-D -arabino-hexopyranosyl-(1®4)- O-(1R)-2,6-dideoxy-D-arabinohexopyranosylidene-(1®3-4)-O-6-deoxy-3-C-methyl-b-D-mannopyranosyl(1®3)- O-6-deoxy-4-O-methyl-b-D-galactopyranosyl-(1®4)-2,6-di- O-methyl-b-Dmannopyranoside O-3-C -méthyl-4-O-méthyl-3-nitro-2,3,6-tridésoxy-a-L- arabino-hexopyranosyl(1 ®3)- O-4- O-(3,5-dichloro-4-hydroxy-2-méthoxy-6-méthylbenzoyl)-2,6didésoxy- b- D-arabino -hexopyranosyl-(1 ®4)- O-(1 R )-2,6-didésoxy-D- arabino hexopyranosylidène-(1 ®3-4)-O-3-C -méthyl-6-désoxy-b- D-mannopyranosyl(1 ®3)-O-4-O-méthyl-6-désoxy- b-D-galactopyranosyl-(1®4)-2,6-di -O-méthyl-bD-mannopyranoside de O-(1R)-4- O-(2,4-dihydroxy-6-méthylbenzoyl)-2,3- Ométhylène-D-xylopyranosylidène-(1®3-4)-a-L-lyxopyranosyle O-2,3,6-tridesoxi-3-C-metil-4-O-metil-3-nitro-a-L-arabino -hexopiranosil-(1®3)O-2,6-didesoxi-4- O-(3,5-dicloro-6-metoxi-4,2-cresotoil)-b-D-arabinohexopiranosil-(1 ®4)-O-(1R)-2,6-didesoxi-D-arabino-hexopiranosilideno(1®3-4)- O-6-desoxi-3-C-metil-b-D- manopiranosil-(1®3)-O-6-desoxi4-O-metil-b-D-galactopiranosil-(1®3)-2,6-di-O-metil-b-D-manopiranósido de O(1R)-2,3-O-metileno-4-O-(6-metil-b-resorciloil)-D-xilopiranosilideno(1®3-4)-a-L-lixopiranosilo C70H97Cl2NO38
évernimicine
evernimicina
O HO CH3 O O OH O H3C O O O O
O
O
OH
H3C O CH3 CH3 OO CH3 H3C OO O CH3 CH3 NO2 H3C Cl OH O O O O OCH3 Cl OH CH3 O O HO
CH3 OO O
O OH O
CH3
OH
193
RECOMMENDED INN: List 44
WHO Drug Information, Vol. 14, No. 3, 2000
everolimusum everolimus
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro9,27-dihydroxy-3-[(1R)-2-[(1 S,3 R,4 R)-4-(2-hydroxyethoxy)3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]= oxaazacyclohentriacontine-1,5,11,28,29(4H,6 H,31H)-pentone (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18dihydroxy-12-[(1 R)-2-[(1S,3 R,4 R)-4-(2-hydroxyéthoxy)-3méthoxycyclohexyl]-1-méthyléthyl]-19,30-diméthoxy-15,17,21,23,29,35hexaméthyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta16,24,26,28-tétraène-2,3,10,14,20-pentone (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahidro9,27-dihidroxi-3-[(1R)-2-[(1S,3 R,4R)-4-(2-hidroxietoxi)-3-metoxiciclohexil]1-metiletil]-10,21-dimetoxi-6,8,12,14,20,26-hexametil-23,27-epoxi3H-pirido[2,1-c][1,4]oxaazaciclohentriacontina-1,5,11,28,29(4H,6H,31H)pentona C53H83NO14 OH
évérolimus
everolimus
H H H3CO
O
H H O H O N O H3C O
CH3 H O
H OH O H
OH H O
H3C H CH3 CH3
OCH3 H3C H H CH3
H OCH3 H
ezlopitantum ezlopitant
(2S,3S)-2-(diphenylmethyl)-3-[(5-isopropyl-2-methoxybenzyl)amino]= quinuclidine (2S,3S)-2-(diphénylméthyl)-N-[2-méthoxy-5-(1-méthyléthyl)benzyl]1-azabibyclo[2.2.2]octan-3-amine (2S,3S)-2-(difenilmetil)-3-[(5-isopropil-2-metoxibencil)amino]quinuclidina
ezlopitant
ezlopitant
194
WHO Drug Information, Vol. 14, No. 3, 2000
RECOMMENDED INN: List 44
C31H38N2O
H3CO H H H N N CH3 CH3
fiduxosinum fiduxosin
8-phenyl-3-[4-[(3aR,9bR)-1,3a,4,9b-tetrahydro-9-methoxy[1]benzopyrano= [3,4-c]pyrrol-2(3H)-yl]butyl]pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine2,4(1 H,3H)-dione 3-[4-[(3aR ,9bR)-9-méthoxy-1,3a,4,9b-tétrahydro[1]benzopyrano[3,4c]pyrrol-2(3H)-yl]butyl]-8-phénylpyrazino[2',3':4,5]thiéno[3,2-d]pyrimidine2,4(1H,3H )-dione 8-fenil-3-[4-[(3aR,9bR)-1,3a,4,9b-tetrahidro-9-metoxi[1]benzopirano[3,4-c]= pirrol-2(3H)-il]butil]pirazino[2',3':4,5]tieno[3,2-d]pirimidina-2,4(1H,3H)-diona C30H29N5O4S N S O OCH3 H N N O O H NH N
fiduxosine
fiduxosina
figopitantum figopitant
(S)- N-[bis(3,5-trifluoromethyl)phenethyl]-4-(cyclopropylmethyl)-N -methyla-phenyl-1-piperazineacetamide (2S)-N-[2-[3,5-bis(trifluorométhyl)phényl]éthyl]-2-[4-(cyclopropylméthyl)= pipérazin-1-yl]-N-méthyl-2-phénylacétamide (S)-N-[bis(3,5-trifluorometil)fenetil]-4-(ciclopropilmetil)-N-metil-a-fenil1-piperazinaacetamida C27H31F6N3O CF3 N N H O N CH3 CF3
figopitant
figopitant
195
RECOMMENDED INN: List 44
WHO Drug Information, Vol. 14, No. 3, 2000
implitapidum implitapide
(aS)-a-[a-(2,4-dimethyl-9H-pyrido[2,3-b]indol-9-yl)-p-tolyl]N-[(aR)- a-(hydroxymethyl)benzyl]cyclopentaneacetamide (2S)-2-cyclopentyl-2-[4-[(2,4-diméthyl-9H-pyrido[2,3-b]indol9-yl)méthyl]phényl]-N-[(1R)-2-hydroxy-1-phényléthyl]acétamide (aS)-a-[a-(2,4-dimetil-9H-pirido[2,3-b]indol-9-il)-p-tolil]N-[(aR)-a-(hidroximetil)bencil]ciclopentanoacetamida C35H37N3O2
implitapide
implitapida
N N H3C CH3
O
H N H OH
H
irampanelum irampanel irampanel irampanel
5-[o-[2-(dimethylamino)ethoxy]phenyl]-3-phenyl-1,2,4-oxadiazole N,N-diméthyl-2-[2-(3-phényl-1,2,4-oxadiazol-5-yl)phénoxy]éthanamine 5-[o-[2-(dimetilamino)etoxi]fenil]-3-fenil-1,2,4-oxadiazol C18H19N3O2 CH3 H3C N
O
O N N
irofulvenum irofulven
(R)-6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro[cyclopropane1,5'-[5H]inden]-7'(6'H)-one (6R)-6-hydroxy-3-(hydroxyméthyl)-2,4,6-triméthylspiro[cyclopropane1,5-[5H]indén]-7(6H)-one (R)-6'-hidroxi-3'-(hidroximetil)-2',4',6'-trimetilspiro[ciclopropano1,5'-[5H]inden]-7'(6'H)-ona
irofulvène
irofulveno
196
WHO Drug Information, Vol. 14, No. 3, 2000
RECOMMENDED INN: List 44
C15H18O3 O HO H3C CH3 CH3 OH
itriglumidum itriglumide
(R)-2'-(8-azaspiro[4.5]dec-8-ylcarbonyl)-4',6'-dimethyl3-(1-naphthyl)glutaranilic acid acide (3R)-5-[[2-(8-azaspiro[4.5]dec-8-ylcarbonyl)-4,6diméthylphényl]amino]-3-(naphtalén-1-yl)-5-oxopentanoïque ácido (R)-2'-(8-azaspiro[4.5]dec-8-ilcarbonil)-4',6'-dimetil3-(1-naftil)glutaranílico C33H38N2O4 CO2H H O NH H3C O N
itriglumide
itriglumida
CH3
laniceminum lanicemine lanicémine lanicemina
(+)-2-[(S)-b-aminophenethyl]pyridine (+)-(1S)-1-phényl-2-(pyridin-2-yl)éthanamine (+)-2-[(S)-b-aminofenetil]piridina C13H14N2
N H NH2
lusaperidonum lusaperidone
3-[2-(3,4-dihydrobenzofuro[3,2-c]pyridin-2(1H)-yl)ethyl]-2-methyl4H-pyrido[1,2-a]pyrimidin-4-one 3-[2-(3,4-dihydrobenzofuro[3,2- c]pyridin-2(1H)-yl)éthyl]-2-méthyl-4Hpyrido[1,2-a]pyrimidin-4-one 3-[2-(3,4-dihidrobenzofuro[3,2-c]piridin-2(1 H)-il)etil]-2-metil4H-pirido[1,2-a]pirimidin-4-ona
lusapéridone
lusaperidona
197
RECOMMENDED INN: List 44
WHO Drug Information, Vol. 14, No. 3, 2000
C22H21N3O2 N N O CH3 N O
metreleptinum metreleptin métréleptine metreleptina
N-methionylleptin (human) N-méthionylleptine humaine N-metionileptina (humana) C714H1167N191O221S6
M VPIQKVQDDT FIPGLHPILT ENLRDLLHVL TEVVALSRLQ mitumomabum mitumomab
KTLIKTIVTR LSKMDQTLAV AFSKSCHLPW GSLQDMLWQL
INDISHTQSV YQQILTSMPS ASGLETLDSL DLSPGC
SSKQKVTGLD RNVIQISNDL GGVLEASGYS
immunoglobulin G2b (mouse monoclonal BEC2 g2b-chain anti-GD3 ganglioside), disulfide with mouse monoclonal BEC2 k-chain, dimer immunoglobuline G2b, anti-(ganglioside GD3) (chaîne g2b de l’anticorps monoclonal de souris BEC2), dimère du disulfure avec la chaîne k de l’anticorps monoclonal de souris BEC2 inmunoglobulina G2b,anti-(gangliósido GD3)(cadena g2b del anticuerpo monoclonal de ratón BEC2) dímero del disulfuro con la cadena k del anticuerpo monoclonal de ratón BEC2
mitumomab
mitumomab
motexafinum motexafin
9,10-diethyl-20,21-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-4,15dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14dipropanol 3,3'-[9,10-diéthyl-20,21-bis[2-[2-(2-méthoxyéthoxy)éthoxy]éthoxy]4,15-diméthyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloicosène5,14-diyl]dipropan-1-ol 9,10-dietil-20,21-bis[2-[2-(2-metoxietoxi)etoxi]etoxi]-4,15-dimetil-8,11-imino3,6:16,13-dinitrilo-1,18-benzodiazacicloeicosina-5,14-dipropanol
motéxafine
motexafina
198
WHO Drug Information, Vol. 14, No. 3, 2000
RECOMMENDED INN: List 44
C48H67N5O10
H3C
OH
H3C H3C
O O
O
O O
O
N N HN N N CH3 CH3
O
O
H3C
OH
nebostinelum nebostinel nébostinel nebostinel
(S)-4-amino-N-(4,4-dimethylcyclohexyl)glutaramic acid acide (4S)-4-amino-5-[(4,4-diméthylcyclohexyl)amino]-5-oxopentanoïque ácido (S)-4-amino-N-(4,4-dimetilciclohexil)glutarámico C13H24N2O3
H HO2C
NH2
H N CH3 CH3
O
onerceptum onercept
glycoprotein TNF-BP (tumor necrosis factor-binding protein) (human disulfide variant 1) 20-180-récepteur 1 humain du facteur de nécrose tumorale, protéine glycosylée (partie du domaine extracellulaire) glicoproteína TNF-BP (proteína de unión al factor de necrosis tumoral)(disulfuro de la variante 1 humana) C753H1156N228O247S25
onercept
onercept
DSVCPQGKYI CRECESGSFT RDTVCGCRKN KQNTVCTCHA N
* HPQNNSICCT
KCHKGTYLYN SCSKCRKEMG FQCFNCSLCL SCSNCKKSLE *
DCPGPGQDTD QVEISSCTVD * NGTVHLSCQE
ASENHLRHCL QYRHYWSENL GFFLRENECV
CTKLCLPQIE
* glycosylation sites * sites de glycosylation * posiciónes de glicosilación
199
RECOMMENDED INN: List 44
WHO Drug Information, Vol. 14, No. 3, 2000
pegvisomantum pegvisomant
18-L-aspartic acid-21-L-asparagine-120-L-lysine-167-L-asparagine168-L-alanine-171-L-serine-172-L-arginine-174- L-serine-179-L-threonine growth hormone (human), reaction product with polyethylene glycol [18-acide L-aspartique-21-L-asparagine-120-L-lysine-167-L-asparagine -168-L-alanine-171-L-sérine-172-L-arginine-174-L-sérine-179-L-thréonine] hormone humaine de croissance combinée à du polyéthylène glycol producto de reacción con polietilenglicol de la 18-ácido-L-aspártico 21-L-asparagina-120-L-lisina-167-L-asparagina-168-L-alanina-171-L-serina172-L-arginina-174-L-serina-179-L-treoninahormona del crecimiento (humana) * FPTIPLSRLF
pegvisomant
pegvisomant
DNAMLRADRL SLCFSESIPT QFLRSVFANS * GSPRTGQIFK
NQLAFDTYQE PSNREETQQK LVYGASDSNV * QTYSKFDTNS *
FEEAYIPKEQ SNLELLRISL * YDLLKDLEEK * HNDDALLKNY
KYSFLQNPQT LLIQSWLEPV IQTLMGRLED GLLYCFNADM
SRVSTFLRTV
QCRSVEGSCG
F
* pegylation sites * sites de pégylation * posiciónes de pegilación
perflexanum perflexane perflexane perflexano
tetradecafluorohexane tétradécafluorohexane tetradecafluorohexano C6F14 F F3C F F F F F F CF3 F
perflutrenum perflutren perflutrène perflutreno
octafluoropropane octafluoropropane octafluoropropano C3F 8 F3C F F CF3
200
WHO Drug Information, Vol. 14, No. 3, 2000
RECOMMENDED INN: List 44
pinokalantum pinokalant
(±)-3,4-dihydro-6,7-dimethoxy-a-phenyl-N,N-bis(2,3,4trimethoxyphenethyl)-1-isoquinolineacetamide (2RS)-2-(6,7-diméthoxy-3,4-dihydroisoquinoléin-1-yl)-2-phénylN,N-bis[2-(2,3,4-triméthoxyphényl)éthyl]acétamide (±)-3,4-dihidro-6,7-dimetoxi-a-fenil-N,N-bis(2,3,4-trimetoxifenetil)1-isoquinolinacetamida C41H48N2O9 OCH3 OCH3 H N OCH3 N O and enantiomer OCH3 et énantiomère y enantiómero OCH3 OCH3
pinokalant
pinokalant
OCH3 H3CO
posaconazolum posaconazole
4-[p-[4-[p-[[(3R,5 R)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol1-ylmethyl)-3-furyl]methoxy]phenyl]-1-piperazinyl]phenyl]-1-[(1S,2S)-1ethyl-2-hydroxypropyl]- D2-1,2,4-triazolin-5-one 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophényl)-5-(1H-1,2,4-triazol-1-ylméthyl)= tétrahydrofuran-3-yl]méthoxy]phényl]pipérazin-1-yl]phényl]-2-[(1S,2 S)-1éthyl-2-hydroxypropyl]-2,4-dihydro-3 H-1,2,4-triazol-3-one 4-[p-[4-[p-[[(3R,5R)-5-(2,4-difluorofenil)tetrahidro-5-(1H-1,2,4-triazol-1ilmetil)-3-furil]metoxi]fenil]-1-piperazinil]fenil]-1-[(1S,2S)-1-etil-2hidroxipropil]-D2-1,2,4-triazolin-5-ona C37H42F2N8O4
posaconazole
posaconazol
H3 C H 3C
H
O F N N N O H F
N H OH N
O N N N
201
RECOMMENDED INN: List 44
WHO Drug Information, Vol. 14, No. 3, 2000
prinomastatum prinomastat
(S)-2,2-dimethyl-4-[[p-(4-pyridyloxy)phenyl]sulfonyl]3-thiomorpholinecarbohydroxamio acid (3S)- N-hydroxy-2,2-diméthyl-4-[[4-(pyridin-4-yloxy)phényl]sulfonyl]= thiomorpholine-3-carboxamide ácido (S)-2,2-dimetil-4-[[p-(4-piridiloxi)fenil]sulfonil]3-tiomorfolinacarbohidroxámico C18H21N3O5S2 O O OO HO N H H H3C S N S CH3 N
prinomastat
prinomastat
pumafentrinum pumafentrine
(-)-p-[(4aR*,10bS*)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy2-methylbenzo[c][1,6]naphthyridin-6-yl]-N,N-diisopropylbenzamide (-)-4-[(4aR*,10b S*)-9-éthoxy-8-méthoxy-2-méthyl-1,2,3,4,4a,10bhexahydrobenzo[c][1,6]naphtyridin-6-yl]-N,N-bis(1-méthyléthyl)benzamide (-)-p-[(4a R*,10bS*)-9-etoxi-1,2,3,4,4a,10b-hexahidro-8-metoxi2-metilbenzo[c][1,6]naftiridina-6-il]-N,N-diisopropilbenzamida C29H39N3O3 O H3CO H N H3C H3C N CH3 O CH3 N CH3 or enantiomer ou énantiomère o enantiómero CH3
pumafentrine
pumafentrina
H
relcovaptanum relcovaptan
(2S)-1-[[(2R,3S)-5-chloro-3-(o-chlorophenyl)-1-[(3,4-dimethoxyphenyl)= sulfonyl]-3-hydroxy-2-indolinyl]carbonyl]-2-pyrrolidinecarboxamide (2S)-1-[[(2R ,3S)-5-chloro-3-(2-chlorophényl)-1-[(3,4-diméthoxyphényl)= sulfonyl]-3-hydroxy-2,3-dihydro-1H -indol-2-yl]carbonyl]pyrrolidine2-carboxamide (2S)-1-[[(2 R,3S)-5-cloro-3-(o-clorofenil)-1-[(3,4-dimetoxifenil)sulfonil]3-hidroxi-2-indolinil]carbonil]-2-pirrolidinacarboxamida
relcovaptan
relcovaptán
202
WHO Drug Information, Vol. 14, No. 3, 2000
RECOMMENDED INN: List 44
C28H27Cl2N3O7S H3CO H3CO O S OO N H OH Cl N O H NH2
Cl
repiferminum repifermin répifermine repifermina
33-172-keratinocyte growth factor 2 (human) 33-172-facteur 2 humain de croissance du kératinocyte 33-172-factor 2 de crecimiento de queratinocitos (humano) C723H1131N209O204S5
SYNHLQGDVR SILEITSVEI DCKLKERIEE GQKTRRKNTS
WRKLFSFTKY GVVAVKAINS NGYNTYASFN AHFLPMVVHS
FLKIEKNGKV NYYLAMNKKG WQHNGRQMYV
SGTKKENCPY KLYGSKEFNN ALNGKGAPRR
resiquimodum resiquimod
4-amino-2-(ethoxymethyl)-a,a-dimethyl-1H-imidazo[4,5-c]quinoline-1ethanol 1-[4-amino-2-(éthoxyméthyl)-1H-imidazo[4,5-c]quinoléin-1-yl]2-méthylpropan-2-ol 4-amino-2-(etoximetil)-a,a-dimetil-1H-imidazo[4,5-c]quinolina-1-etanol C17H22N4O2 H3C OH CH3 O CH3
résiquimod
resiquimod
N N NH2 N
risarestatum risarestat risarestat
(±)-5-[3-ethoxy-4-(pentyloxy)phenyl]-2,4-thiazolidinedione (5RS)-5-[3-éthoxy-4-(pentyloxy)phényl]thiazolidine-2,4-dione
203
RECOMMENDED INN: List 44
WHO Drug Information, Vol. 14, No. 3, 2000
risarestat
(±)-5-[3-etoxi-4-(pentiloxi)fenil]-2,4-tiazolidinadiona C16H21NO4S O S H O O CH3 NH O and enantiomer et énantiomère y enantiómero
H3C
rubitecanum rubitecan rubitécan
9-nitrocamptothecin (4S)-4-éthyl-4-hydroxy-10-nitro-1,12-dihydro-14H-pyrano[3’,4’:6,7]= indolizino[1,2-b]quinoléine-3,14(4H)-dione 9-nitrocamptotecina C20H15N3O6 O N O2N N HO O CH3 O
rubitecán
sulamserodum sulamserod
N-[2-[4-[2-[(8-amino-7-chloro-1,4-benzodioxan-5yl)carbonyl]ethyl]piperidino]ethyl]methanesulfonamide N-[2-[4-[3-(8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)3-oxopropyl]pipéridin-1-yl]éthyl]méthanesulfonamide N-[2-[4-[2-[(8-amino-7-cloro-1,4-benzodioxan-5-il)carbonil]etil]piperidino]= etil]metanosulfonamida C19H28ClN3O5S O H2N Cl O O N
sulamsérod
sulamserod
H N
S
CH3
O O
tanomastatum tanomastat tanomastat
(S)-3-[(4’-chloro-4-biphenylyl)carbonyl]-2-[(phenylthio)methyl]propionic acid acide (2S)-4-(4’-chlorobiphényl-4-yl)-4-oxo-2-[(phénylsulfanyl)méthyl]= butanoïque
204
WHO Drug Information, Vol. 14, No. 3, 2000
RECOMMENDED INN: List 44
tanomastat
ácido (2S)-4-(4’-clorobifenil-4-il)-4-oxo-2-[(fenilsulfanilo)metil]butanoico C23H19ClO3S Cl
HO2C S H O
tebipenemum tebipenem
(+)-hydroxymethyl (4R,5 S,6 S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3[[1-(2-thiazolin-2-yl)-3-azetidinyl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2carboxylate, 2-pivalate (+)-(4R,5S,6S)-3-[[1-(4,5-dihydrothiazol-2-yl)azétidin-3-yl]sulfanyl]-6-[(1R)1-hydroxyéthyl]-4-méthyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ène-2-carboxylate de [(2,2-diméthylpropanoyl)oxy]méthyle 2-pivalato y (4R,5S,6S)-6-[(1R)-1-hidroxietil]-4-metil-7-oxo-3-[[1-(2-tiazolin2-il)-3-azetidinil]tio]-1-azabiciclo[3.2.0]hept-2-eno-2-carboxilato de metileno C22H31N3O6S2 H3C CH3 O S N N S O O CH3
tébipénem
tebipenem
O O H3C HO N
H H H H CH3
tenofovirum tenofovir ténofovir
[[(R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phosphonic acid acide [[(1R)-2-(6-amino-9H-purin-9-yl)-1méthyléthoxy]méthyl]phosphonique ácido [[(R)-2-(6-amino-9H-purin-9-il)-1-metiletoxi]metil]fosfónico C9H14N5O4P NH2 N N N N O H CH3 O P OH OH
tenofovir
205
RECOMMENDED INN: List 44
WHO Drug Information, Vol. 14, No. 3, 2000
tiplimotidum tiplimotide
D-alanyl-L-lysyl-L-prolyl-L-valyl-L -valyl-L-histidyl-L-leucyl-L-phenylalanyl-Lalanyl-L-asparaginyl-L-isoleucyl-L-valyl-L-threonyl-L-prolyl-L-arginyl- Lthreonyl-L-prolinamide D-alanyl-L-lysyl-L-prolyl-L-valyl-L-valyl-L-histidyl-L-leucyl-L-phénylalanyl-Lalanyl-L-asparaginyl-L-isoleucyl-L-valyl-L-thréonyl-L-prolyl- L-arginyl- Lthréonyl-L-prolinamide D-alanil-L-lisil-L-prolil-L-valil-L-valil-L-histidil-L-leucil-L-fenilalanil-L-alanilL-asparaginil-L-isoleucil-L-valil-L-treonil-L-prolil-L-arginil-L-treonil-L-prolinamida
tiplimotide
tiplimotida
C87H143N25O20 D-Ala
Lys Val
Pro Thr
Val Pro
Val Arg
His Thr
Leu
Phe
Ala
Asn 10
Ile
Pro NH2
valrocemidum valrocemide valrocémide valrocemida
N-(carbamoylmethyl)-2-propylvaleramide N-(2-amino-2-oxoéthyl)-2-propylpentanamide N-(carbamoilmetil)-2-propilvaleramida C10H20N2O2 O H3C H3C N H NH2 O
vardenafilum vardenafil
1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1- f]-as-triazin-2-yl)4-ethoxyphenyl]sulfonyl]-4-ethylpiperazine 2-[2-éthoxy-5-[(4-éthylpipérazin-1-yl)sulfonyl]phényl]-5-méthyl-7propylimidazolo[5,1-f][1,2,4]triazin-4(3H)-one 1-[[3-(3,4-dihidro-5-metil-4-oxo-7-propilimidazo[5,1-f]-as-triazin-2-il)4-etoxifenil]sulfonil]-4-etilpiperazina C23H32N6O4S O O O S N H3C N HN N O N CH3 N
vardénafil
vardenafil
CH3
CH3
206
WHO Drug Information, Vol. 14, No. 3, 2000
RECOMMENDED INN: List 44
vofopitantum vofopitant
(2S,3S)-3-[[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]benzyl]amino]2-phenylpiperidine (2S,3S)-N-[2-méthoxy-5-[5-(trifluorométhyl)-1H-tétrazol-1-yl]benzyl]2-phénylpipéridin-3-amine (2S,3S)-3-[[2-metoxi-5-[5-(trifluorometil)-1H-tetrazol-1-il]bencil]amino]2-fenilpiperidina C21H23F3N6O H3CO H HN H N H F3C N N N N
vofopitant
vofopitant
207
RECOMMENDED INN: List 44
WHO Drug Information, Vol. 14, No. 3, 2000
AMENDMENTS TO PREVIOUS LISTS MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES MODIFICACIONES A LAS LISTAS ANTERIORES Recommended International Nonproprietary Names (Rec. INN): List 43 Dénominations communes internationales recommandées (DCI Rec.): Liste 43 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 43 (WHO Drug Information, Vol. 14, No. 1, 2000)
p. 50
eledoisinum eledoïsine
remplacer le nom par le suivant: élédoïsine
p. 57
idremcinalum idremcinal
remplacer le nom chimique par le suivant: (2R ,3R ,4S,5R ,8R ,9S,10S,11R ,12R )-5-éthyl-3,4-dihydroxy2,4,8,10,12,14-hexaméthyl-9-[(3- C -méthyl-3-O-méthyl-2,6-didésoxy- a-L-ribohexopyranosyl)oxy]-11-[[3-[méthyl(1-méthyléthyl)amino]-3,4,6-tridésoxy- b-Dxylo -hexopyranosyl]oxy]-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-én-7-one
p. 59
lasofoxifenum lasofoxifène
remplacer le nom chimique par le suivant: (-)-(5 R*,6S*)-6-phényl-5-[4-[2-(pyrrolidin-1-yl)éthoxy]phényl]5,6,7,8-tétrahydronaphtalén-2-ol
p. 64
pimecrolimusum pimécrolimus
remplacer le nom chimique par le suivant: (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-12-[(E)-2[(1R,3R,4S)-4-chloro-3-méthoxycyclohexyl]-1-méthyléthényl]17-éthyl-1,14-dihydroxy-23,25-diméthoxy-13,19,21,27-tétraméthyl11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ène-2,3,10,16-tétrone
p. 66
sarakalimum sarakalim
remplacer le nom chimique par le suivant: N -[[2,2-diméthyl-4-(2-oxopyridin-1(2H)-yl)-6-(trifluorométhyl)-2H 1benzopyran-3-yl]méthyl]- N-hydroxyacétamide
208
WHO Drug Information, Vol. 14, No. 3, 2000
RECOMMENDED INN: List 44
Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances will be reproduced in uneven numbers of proposed INN lists only. Les textes de la Procédure à suivre en vue de choix de dénominations communes internationales recommandées pour les substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internatio-nales applicables aux substances pharmaceutiques ont été publiés avec la liste 81 des DCI proposées et seront, à nouveau, publiés avec la prochaine liste des DCI proposées. El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sus-tancias farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacio-nales para sustancias farmacéuticas aparece solamente en los números impares de las listas de DCI propuestas.
209